The FDA and CDC are investigating a Salmonella outbreak tied to moringa leaf powder from India. Member’s Mark Super Greens ...

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company ...

The U.S. Food and Drug Administration recalled more than 580,000 bottles of a blood pressure medication. Is your medication ...

FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug ...

Compass Pathways, which is developing a psilocybin treatment for severe depression, said it now expects an earlier decision ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months.

The pharma company's newer immunology drugs, Skyrizi and Rinvoq, have delivered robust sales growth that's proving to be the ...

By last winter, medetomidine was showing up in 70% of illicit opioid samples tested in Philly, along with other unregulated substances and synthetic opioids like fentanyl.

It was the latest shockwave to sweep through an agency beset by all kinds of tumult in recent months. In interviews, ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...